Catalent amps up plans to manufacture J&J's Covid-19 vaccine, adding vial filling line in Italy

John Carroll

Editor & Founder

A little more than a year after Catalent CEO John Chiminski acquired Bristol Myers Squibb’s manufacturing facility in Anagni, Italy, the big CDMO is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Catalent amps up plans to manufacture J&J's Covid-19 vaccine, adding vial filling line in Italy

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Catal­ent amps up plans to man­u­fac­ture J&J's Covid-19 vac­cine, adding vial fill­ing line in Italy

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Catalent amps up plans to manufacture J&J's Covid-19 vaccine, adding vial filling line in Italy